hVIVO (LON:HVO) Stock Crosses Above 50 Day Moving Average – Here’s Why

hVIVO plc (LON:HVO)’s stock price passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 6.99 and traded as high as GBX 8.70. hVIVO shares last traded at GBX 8.40, with a volume of 1,180,797 shares changing hands.

Analyst Ratings Changes

A number of analysts have commented on HVO shares. Peel Hunt reiterated an “add” rating and issued a GBX 10 price target on shares of hVIVO in a research note on Thursday, November 20th. Shore Capital Group reaffirmed a “buy” rating and issued a GBX 25 target price on shares of hVIVO in a report on Thursday, January 29th. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of GBX 17.50.

hVIVO Stock Down 0.1%

The company has a debt-to-equity ratio of 33.70, a quick ratio of 1.16 and a current ratio of 1.60. The firm has a fifty day simple moving average of GBX 6.99 and a 200-day simple moving average of GBX 7.30. The firm has a market cap of £57.64 million, a price-to-earnings ratio of 10.89 and a beta of 0.97.

Insider Activity

In related news, insider Yamin Mo’ Khan bought 3,310,405 shares of hVIVO stock in a transaction that occurred on Monday, December 15th. The stock was acquired at an average price of GBX 6 per share, with a total value of £198,624.30. Also, insider Stephen Pinkerton purchased 520,000 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was bought at an average price of GBX 6 per share, for a total transaction of £31,200. Insiders own 5.25% of the company’s stock.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.